Biomea Fusion, Inc. Share Price

Biomea Fusion, Inc. Share Price

NASDAQ: BMEA | Micro Cap
$0.63
-$0.01 (-1.94%) Last updated on 30 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Biomea Fusion, Inc. Stock Performance

Open
$0.65
Prev. Close
$0.64
Circuit Range
N/A
Day Range
$0.62 - $0.65
Year Range
$0.56 - $2.23
Volume
13,732
Average Traded
$0.63

Biomea Fusion, Inc. Share Price Today

As of 30 October 2026, Biomea Fusion, Inc.'s share price is $0.63. The stock opened at $0.65, compared to its previous close of $0.64. During today's trading session, Biomea Fusion, Inc.'s share price traded between $0.62 and $0.65, with an average price of $0.63. Over the past 52 weeks, the stock has recorded a high of $2.23 and a low of $0.56. In terms of performance, Biomea Fusion, Inc.'s share price has declined by 53.81% over the last six months and is down 54.15% on a year-on-year basis.

Biomea Fusion, Inc. Share Price Chart

Line chart of the Biomea Fusion, Inc. price trend over the selected period. The price fell overall, ranging from 0.62 to 0.66, ending at 0.63.
$0.62$0.65
L
Show Current Price
H

Biomea Fusion, Inc. Stock Fundamentals & Key Indicators

Market Cap
$32.81M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.45
Revenue (TTM)
$0.00
Return On Equity (TTM)
-268.09%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
49.24%

Biomea Fusion, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$16.41$4.61-$12.42-$8.33
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A128.09%-369.41%32.93%

Biomea Fusion, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$81.83-$117.26-$138.43-$61.80
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-43.30%-18.05%55.36%

About Biomea Fusion, Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Biomea Fusion, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$1.31
$0.63
-52.06%
Sep 2026
$1.68
$1.31
-22.26%
Aug 2026
$1.13
$1.69
+44.02%
Jul 2026
$1.48
$1.17
-20.41%
Jun 2026
$1.39
$1.47
+6.14%
May 2026
$1.34
$1.39
+1.84%
Apr 2026
$1.53
$1.36
-9.93%
Mar 2026
$1.37
$1.51
+10.22%
Feb 2026
$1.11
$1.37
+22.32%
Jan 2026
$1.25
$1.12
-8.94%
Dec 2025
$1.03
$1.23
+10.81%
Nov 2025
$1.38
$1.11
-18.98%

BMEA Share Price FAQs